ALOXE3 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-7856R-Cy5.5-100uL |
| Product Name | ALOXE3 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Pig, Horse |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human ALOXE3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 59344 |
| Subcellular location | Cytoplasm |
| Synonyms | ALOXE3; Arachidonate lipoxygenase 3; e LOX 3; E LOX; e-LOX-3; eLOX3; Epidermal lipoxygenase; Epidermis-type lipoxygenase 3; Lipoxygenase 3; LOXE3_HUMAN. |
| Background | Introduces molecular oxygen into polyunsaturated fatty acids. Exact substrate is not known.Tissue specificity:Predominantly expressed in skin.Involvement in diseaseDefects in ALOXE3 are a cause of non-bullous congenital ichthyosiform erythroderma (NCIE). NCIE is a non-bullous ichthyosis, a skin disorder characterized by abnormal cornification of the epidermis. Most affected individuals are born with a tight, shiny, translucent covering called collodion membrane. The collodion membrane subsequently evolves into generalized scaling and intense redness of the skin. Clinical features are milder than in lamellar ichthyoses and demonstrate a greater variability in the intensity of erythema, size and type of scales. In contrast to lamellar ichthyoses, scales are usually white, fine and powdery, and palms and soles are severely affected. Patients suffer from palmoplantar keratoderma, often with painful fissures, digital contractures, and loss of pulp volume. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is ALOXE3 Polyclonal Antibody, Cy5.5 Conjugated (BS-7856R-CY5-5) validated for, and at what dilution?
BS-7856R-CY5-5 is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should BS-7856R-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise ALOXE3 Polyclonal Antibody, Cy5.5 Conjugated (BS-7856R-CY5-5)?
KLH conjugated synthetic peptide derived from human ALOXE3
What are the excitation and emission wavelengths of the Cy5.5 conjugate (BS-7856R-CY5-5)?
Cy5.5 on BS-7856R-CY5-5: excitation / emission 675nm/694nm.